cmf chemotherapy for breast cancer in older adults
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 70 years of age or older
- Have a confirmed diagnosis of breast cancer (adenocarcinoma) that was verified by biopsy or surgery within the last 3 months
- Have a recent pathology report showing HER2, estrogen receptor, and progesterone receptor status
- Be in generally good health (able to carry out daily activities) — your doctor will assess this
- Have adequate kidney, liver, and blood cell counts (these are checked with routine labs)
- For some groups: the cancer must be triple-negative (all three receptor tests negative) and you must have had at least one dose of neoadjuvant chemotherapy with carboplatin and paclitaxel with or without pembrolizumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy combination (CMC) for people with early-stage, hormone receptor-positive, HER2-negative breast cancer who have a high risk of recurrence. It aims to understand if this oral regimen is effective and tolerable.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
This trial tests whether women aged 65 and older with a certain type of early breast cancer can safely skip chemotherapy and instead receive a pill that helps stop cancer cells from growing. The goal is to reduce treatment side effects while keeping the cancer from coming back.
This trial tests whether a pill (a CDK4/6 inhibitor) used alone, without chemotherapy, is effective for older women with early-stage hormone-positive breast cancer. The goal is to reduce the risk of cancer returning while avoiding the side effects of chemo.
This trial tests whether adding moxifloxacin (an antibiotic) to standard chemotherapy helps people with metastatic triple-negative breast cancer live longer or respond better. You may qualify if your cancer has the right lab markers and you haven’t had treatment for metastatic disease yet.
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.